These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18462058)

  • 21. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hearing focuses on price of Norplant; Wyeth pledges discount for public sector.
    Wash Memo Alan Guttmacher Inst; 1993 Nov; (18):3-4. PubMed ID: 12318533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of human parasitic diseases: Context and overview.
    Molyneux DH
    Adv Parasitol; 2006; 61():1-45. PubMed ID: 16735161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Out with the old, in with the young: lifetime community rating.
    Hindle D
    Aust Health Rev; 1999; 22(1):156-60. PubMed ID: 10387898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On the critical list: the US institution of medicine.
    Supri S; Malone K
    Am J Med; 2011 Mar; 124(3):192-3. PubMed ID: 21396498
    [No Abstract]   [Full Text] [Related]  

  • 26. [Economical evaluation of drugs. A steering method for the pharmaceutical sector of the 1990's?].
    Grund J; Husbyn H
    Tidsskr Nor Laegeforen; 1994 Mar; 114(8):947-50. PubMed ID: 8191475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hurdles in tissue engineering/regenerative medicine product commercialization: a survey of North American academia and industry.
    Johnson PC; Bertram TA; Tawil B; Hellman KB
    Tissue Eng Part A; 2011 Jan; 17(1-2):5-15. PubMed ID: 20726816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Supplemental health insurance: did Croatia miss an opportunity?
    Langenbrunner JC
    Croat Med J; 2002 Aug; 43(4):403-7. PubMed ID: 12187517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reforms in the Greek pharmaceutical market during the financial crisis.
    Vandoros S; Stargardt T
    Health Policy; 2013 Jan; 109(1):1-6. PubMed ID: 22959163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mechanism and implication of regulation of the pricing of essential medicines in the private pharmaceutical sector in Mali].
    Maïga D; Maïga S; Maïga MD
    Med Trop (Mars); 2010 Apr; 70(2):184-8. PubMed ID: 20486360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual choice health insurance policy: a proposal and a cost analysis.
    Cheng J; Ives JC
    J Health Care Finance; 2009; 36(2):60-70. PubMed ID: 20499722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical sector in transition--a cross sectional study in Vietnam.
    Falkenberg T; Nguyen TB; Larsson M; Nguyen TD; Tomson G
    Southeast Asian J Trop Med Public Health; 2000 Sep; 31(3):590-7. PubMed ID: 11289028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regenerative medicine. The industry comes of age.
    Mason C
    Med Device Technol; 2007; 18(2):25-30. PubMed ID: 17494498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regenerative medicine research at Pfizer. Interview with Ruth McKernan.
    McKernan R
    Regen Med; 2011 Nov; 6(6 Suppl):62-4. PubMed ID: 21999263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmaceutical industry research and cost savings in community-acquired pneumonia.
    Kessler LA; Waterer GW; Barca R; Wunderink RG
    Am J Manag Care; 2002 Sep; 8(9):798-800. PubMed ID: 12234020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
    Falit BP
    Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
    [No Abstract]   [Full Text] [Related]  

  • 39. Advanced Tissue Sciences Inc.: learning from the past, a case study for regenerative medicine.
    Pangarkar N; Pharoah M; Nigam A; Hutmacher DW; Champ S
    Regen Med; 2010 Sep; 5(5):823-35. PubMed ID: 20868336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health reform accelerates changes in the pharmaceutical industry.
    Spatz ID
    Health Aff (Millwood); 2010 Jul; 29(7):1331-6. PubMed ID: 20606183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.